We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing
Read MoreHide Full Article
Clovis Oncology, Inc. announced that the European Medicines Agency ("EMA") has accepted its type II variation to the marketing authorization seeking label expansion of Rubraca in Europe.
We remind investors that Rubraca was approved in Europe as monotherapy for the treatment of platinum-sensitive and relapsing ovarian cancer patients with BRCA-mutation in third- or later-line setting in May. With the latest application, the company is seeking label expansion of the drug as maintenance treatment for ovarian cancer patients irrespective of BRCA-mutation and who are in a complete or partial response to platinum based chemotherapy.
A potential approval for the label expansion will boost the prospect of the drug in Europe as it will reach a wider population base of patients with ovarian cancer.
Rubraca is approved for the expanded indication in the United States with approval as maintenance treatment received in April.
Clovis’ shares have declined 33% so far this year compared with the industry’s 6.4% decline.
The regulatory application includes promising data from the confirmatory phase III study, ARIEL 3. The drug showed a significant delay in recurrence of the disease in BRCA mutant or HRD positive ovarian cancer patients in the study.
Rubraca competes with AstraZeneca’s (AZN - Free Report) Lynparza and Tesaro, Inc.'s Zejula. Lynparza and Zejula have an advantage over Rubraca as the drugs are already approved in patients irrespective of BRCA-mutation status.
Meanwhile, an early-stage study is being conducted by Pfizer (PFE - Free Report) , on its PARP inhibitor, talazoparib, in several advanced or recurrent solid tumors.
The year 2018 is progressing well for Clovis with two regulatory approvals for Rubraca.The National Comprehensive Cancer Network added the drug as maintenance therapy for third or later-line setting to its clinical practice guidelines for ovarian cancer.
These positive developments will certainly boost sales of the drug, driving the company’s topline going forward.
Apart from these, a late-stage confirmatory study is evaluating Rubraca compared with chemotherapy on patients in third or later-line settings. The company is also developing the drug in additional indications like prostrate, breast and pancreatic cancers.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing
Clovis Oncology, Inc. announced that the European Medicines Agency ("EMA") has accepted its type II variation to the marketing authorization seeking label expansion of Rubraca in Europe.
We remind investors that Rubraca was approved in Europe as monotherapy for the treatment of platinum-sensitive and relapsing ovarian cancer patients with BRCA-mutation in third- or later-line setting in May. With the latest application, the company is seeking label expansion of the drug as maintenance treatment for ovarian cancer patients irrespective of BRCA-mutation and who are in a complete or partial response to platinum based chemotherapy.
A potential approval for the label expansion will boost the prospect of the drug in Europe as it will reach a wider population base of patients with ovarian cancer.
Rubraca is approved for the expanded indication in the United States with approval as maintenance treatment received in April.
Clovis’ shares have declined 33% so far this year compared with the industry’s 6.4% decline.
The regulatory application includes promising data from the confirmatory phase III study, ARIEL 3. The drug showed a significant delay in recurrence of the disease in BRCA mutant or HRD positive ovarian cancer patients in the study.
Rubraca competes with AstraZeneca’s (AZN - Free Report) Lynparza and Tesaro, Inc.'s Zejula. Lynparza and Zejula have an advantage over Rubraca as the drugs are already approved in patients irrespective of BRCA-mutation status.
Meanwhile, an early-stage study is being conducted by Pfizer (PFE - Free Report) , on its PARP inhibitor, talazoparib, in several advanced or recurrent solid tumors.
The year 2018 is progressing well for Clovis with two regulatory approvals for Rubraca.The National Comprehensive Cancer Network added the drug as maintenance therapy for third or later-line setting to its clinical practice guidelines for ovarian cancer.
These positive developments will certainly boost sales of the drug, driving the company’s topline going forward.
Apart from these, a late-stage confirmatory study is evaluating Rubraca compared with chemotherapy on patients in third or later-line settings. The company is also developing the drug in additional indications like prostrate, breast and pancreatic cancers.
Clovis Oncology, Inc. Price
Clovis Oncology, Inc. Price | Clovis Oncology, Inc. Quote
Zacks Rank
Clovis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>